Mathys Kenneth C, Cohen Kenneth L, Bagnell Charles R
Department of Ophthalmology, Microscopy Services Laboratory, University of North Carolina at Chapel Hill, School of Medicine, University of North Carolina Hospitals, Chapel Hill, North Carolina 27599-7040, USA.
J Cataract Refract Surg. 2008 Mar;34(3):465-9. doi: 10.1016/j.jcrs.2007.10.047.
To describe and identify unknown opaque material between the optic of an AR40 intraocular lens (IOL) injected with the Emerald Series implantation system (both AMO, Inc.) and the posterior capsule at the conclusion of routine phacoemulsification to prevent an outbreak of toxic anterior segment syndrome (TASS).
Ambulatory care center operating room, University of North Carolina Hospitals and Department of Ophthalmology, University of North Carolina School of Medicine at Chapel Hill, Chapel Hill, North Carolina, USA.
After coaxial phacoemulsification in multiple patients, opaque material was present between the optic of a posterior chamber IOL and the posterior capsule. Although there was no TASS, the material was removed from 2 eyes and analyzed with scanning electron microscopy (SEM) and x-ray microanalysis (XRM). Similarly, crystalline lens, Klenzyme (Steris Corp.), Viscoat (sodium hyaluronate 3.0%-chondroitin sulfate 4.0%), and Provisc (sodium hyaluronate 1.0%) were analyzed.
On SEM, the material had an irregular undulating surface similar to that of Provisc. Viscoat and the crystalline lens had smoother surfaces. On XRM, the material contained sodium, chlorine, and calcium, like Viscoat and Provisc, and phosphorous and sulfur, like Viscoat. The material also contained silicone, magnesium, aluminum, titanium, iron, and zinc. Klenzyme had smaller peaks of sodium, chlorine, and calcium and a higher carbon background than the unknown material.
The material was likely ophthalmic viscosurgical device that was chemically and structurally altered by the cleaning and sterilization process. The silicone and metallic elements were probably from the Emerald Series implantation system as the disposable cartridge is coated with silicone and the reusable injector is metal.
描述并识别在使用Emerald系列植入系统(均为AMO公司产品)向AR40人工晶状体(IOL)注入过程中,于常规超声乳化术结束时,人工晶状体光学部与后囊之间出现的不明不透明物质,以预防毒性眼前节综合征(TASS)的爆发。
美国北卡罗来纳州教堂山北卡罗来纳大学医院眼科门诊手术中心及北卡罗来纳大学医学院眼科。
在多例患者进行同轴超声乳化术后,后房型人工晶状体光学部与后囊之间出现了不透明物质。尽管未发生TASS,但从2只眼中取出该物质,并用扫描电子显微镜(SEM)和X射线微分析(XRM)进行分析。同样,对晶状体、Klenzyme(施特力公司)、Viscoat(3.0%透明质酸钠 - 4.0%硫酸软骨素)和Provisc(1.0%透明质酸钠)也进行了分析。
在SEM下,该物质具有不规则起伏的表面,类似于Provisc。Viscoat和晶状体表面更光滑。在XRM下,该物质含有钠、氯和钙,与Viscoat和Provisc一样,还含有磷和硫,与Viscoat一样。该物质还含有硅、镁、铝、钛、铁和锌。Klenzyme的钠、氯和钙峰值较小,且碳背景比不明物质更高。
该物质可能是眼科粘弹剂装置,在清洁和消毒过程中发生了化学和结构改变。硅和金属元素可能来自Emerald系列植入系统,因为一次性药筒涂有硅,可重复使用注射器为金属材质。